Search

Your search keyword '"Rajender Reddy, K."' showing total 4 results
Start Over Author "Rajender Reddy, K." Language undetermined
4 results on '"Rajender Reddy, K."'

1. Hepatitis B

Author

Weakley and Rajender Reddy K

Subjects
Gastroenterology
Abstract

The management of acute HBV infection is supportive. Specific treatment is not indicated for HBV carriers because they often have no evidence of liver injury, and, further, do not respond to currently available therapies. Interferon monotherapy is best indicated for patients with chronic replicating HBV infection and evidence of chronic hepatitis. There is an increased likelihood of clearing HBsAg with interferon monotherapy as compared to lamivudine. Lamivudine is an oral nucleoside analog that is better tolerated than interferon. The clinical situations for its use are far more than interferon monotherapy. Lamivudine should be used in patients with decompensated cirrhosis and also in transplantation, both before and after transplantation. The post-transplant use of hepatitis B immune globulin (HBIG) and lamivudine combination therapy may be better for recipients who are identified in a replicative phase prior to transplantation. Hepatitis B coinfection with one or more viruses, HCV, HDV, or HIV, may occur. Both interferon and lamivudine have been useful in these patients. However, the data are sparse and heterogeneous. Therapy with one or both drugs will have to be tailored to the clinical situation. Combination therapy with immunomodulatory and/or antiviral drugs are what we will be looking toward in the future.

Published
1999

2. Chronic kidney disease after liver transplantation in human immunodeficiency virus/hepatitis C virus-coinfected recipients versus human immunodeficiency virus-infected recipients without hepatitis C virus: results from the National Institutes of Health multi-site study

Author

Bahirwani, Ranjeeta, Barin, Burc, Olthoff, Kim, Stock, Peter, Murphy, Barbara, Rajender Reddy, K, and Solid Organ Transplantation in HIV: Multi-Site Study Investigators

Subjects
Adult, Male, Kidney Disease, Chronic Liver Disease and Cirrhosis, Clinical Sciences, Renal and urogenital, HIV Infections, Hepatitis, Multi-Site Study Investigators [Solid Organ Transplantation in HIV], Hepatitis - C, Risk Factors, Clinical Research, Prevalence, Humans, Renal Insufficiency, Chronic, Transplantation, Coinfection, Incidence, Liver Disease, Age Factors, Evaluation of treatments and therapeutic interventions, Organ Transplantation, Middle Aged, Hepatitis C, United States, Liver Transplantation, Infectious Diseases, Emerging Infectious Diseases, Good Health and Well Being, National Institutes of Health (U.S.), Creatinine, 6.1 Pharmaceuticals, Multivariate Analysis, HIV/AIDS, Female, Surgery, Digestive Diseases, Infection, Liver Failure, Glomerular Filtration Rate
Abstract

Hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are both associated with chronic kidney disease (CKD), a major complication after orthotopic liver transplantation (OLT). The aim of this study was to assess predictors of post-OLT CKD in HIV/HCV-coinfected recipients versus HIV-infected recipients without HCV (HIV/non-HCV recipients). Data from a National Institutes of Health study of 116 OLT recipients (35 HIV/non-HCV recipients and 81 HIV/HCV-coinfected recipients) from 2003 to 2010 (Solid Organ Transplantation in HIV: Multi-Site Study) were analyzed for the pretransplant CKD prevalence [estimated glomerular filtration rate (eGFR)

Published
2013

4. Predicting Early and Sustained Virological Responses in Prior Nonresponders to Pegylated Interferon alpha-2b Plus Ribavirin Retreated With Peginterferon alpha-2a Plus Ribavirin and the Benefit-Risk Ratio of Retreatment

Author

K. Rajender Reddy, Greg Hooper, G. Teuber, Antonio Craxì, Diethelm Messinger, Adrian M. Di Bisceglie, Patrick Marcellin, Donald M. Jensen, Carlos E. Brandao-Mello, Fernando Tatsch, Cynthia Wat, Antonio Olveira Martin, B. Freilich, Pietro Andreone, Marcellin, P, Craxi, A, Brandao-Mello, CE, Di Bisceglie, AM, Andreone, P, Freilich, B, Rajender Reddy, K, Olveira Martín, A, Teuber, G, Messinger, D, Hooper, G, Wat, C, Tatsch, F, Jensen, DM, Patrick Marcellin, Antonio Craxi, Carlos E. Brandao-Mello, Adrian M. Di Bisceglie, Pietro Andreone, Bradley Freilich, K. Rajender Reddy, Antonio Olveira Martín, Gerlinde Teuber, Diethelm Messinger, Greg Hooper, Cynthia Wat, Fernando Tatsch, and Donald M. Jensen

Subjects
Adult, Male, medicine.medical_specialty, Time Factors, Interferon alpha-2, Antiviral therapy, Antiviral Agents, Gastroenterology, Polyethylene Glycols, law.invention, chemistry.chemical_compound, Pharmacotherapy, Randomized controlled trial, nonresponder, Predictive Value of Tests, law, Internal medicine, Ribavirin, chronic hepatitis C, Humans, Medicine, peginterferon, Adverse effect, Randomized Controlled Trials as Topic, business.industry, Interferon-alpha, virus diseases, Hepatitis C, Hepatitis C, Chronic, Middle Aged, medicine.disease, retreatment, sustained virological response, Recombinant Proteins, digestive system diseases, Regimen, Treatment Outcome, chemistry, Predictive value of tests, Relative risk, Retreatment, Drug Therapy, Combination, Female, business
Abstract

GOALS: To evaluate the predictive value of complete early virological response (cEVR) on sustained virological response (SVR) following retreatment with peginterferon alpha-2a (40 kDa) plus ribavirin in previous nonresponders to peginterferon alpha-2b (12 kDa). BACKGROUND: In the randomized multinational retreatment with Pegasys in patients not responding to PegIntron therapy study, a 72-week regimen of peginterferon alpha-2a (40 kDa) plus ribavirin improved SVR rates over a standard 48-week regimen in previous nonresponders to peginterferon alpha-2b (12 kDa). cEVR, defined as hepatitis C virus RNA

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results